A cytotoxic gene therapy targeting SOX9-positive therapy-resistant medulloblastoma
Neuro-Oncology Pediatrics · 2025
DOI: 10.1093/neuped/wuaf005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Pediatrics, 2025. Verfasst von Tong Lin und 8 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Swedish Childhood Cancer Fund, The Swedish Cancer Society, The Swedish Research Council.
Abstract (Originalsprache)
Background
The transcription factor SOX9 is associated with poor prognosis and therapy resistance in medulloblastoma, one of the most common malignant pediatric brain tumors. While SOX9 knockdown inhibits tumor recurrence in animal models, no direct SOX9 inhibitors are currently available for clinical use. SOX9 functions as a potent activator of a minimal COL2A1 enhancer that can work as a SOX9-specific response element. In this study, we aimed to engineer this response element to identify therapy-resistant tumor cells and further use it as a gene therapy to selectively target SOX9-expressing medulloblastoma.
Methods
We employed lentiviral and adeno-associated virus (AAV) vectors, flow cytometry, immunohistochemistry, immunoblotting, in vitro cell models, and in vivo orthotopic mouse models to track and eliminate therapy-resistant medulloblastoma cells.
Results
We demonstrated that SOX9-positive cells can be efficiently labeled using a reporter construct containing four tandem SOX9-specific response elements coupled to a minimal promoter (S9RE) driving expression of enhanced green fluorescent protein and luciferase. Furthermore, S9RE was used in an AAV vector to drive expression of herpes simplex virus thymidine kinase (TK), enabling a suicide gene therapy approach wherein ganciclovir selectively kills dividing SOX9-positive tumor cells.
Conclusions
This AAV-based gene therapy, when combined with fractionated radiation, synergized with standard therapy to effectively eliminate SOX9-positive medulloblastoma cells in vitro and in vivo. The findings support the potential of SOX9-driven gene therapy as a targeted strategy to overcome therapy resistance in malignant pediatric brain tumors.
Förderung
- The Swedish Childhood Cancer Fund
- The Swedish Cancer Society
- The Swedish Research Council
- The Swedish Brain Foundation
- The Sjöberg Foundation
- European Research Council PoC
- The Erling Persson Foundation
- Knut and Alice Wallenberg Foundation
Zitieren
APA
Lin, T., Hutter, S., Vikström, E., Rosén, G., Bergström, T., Holmberg, K. O., Zhao, M., Giraud, G., & Swartling, F. J. (2025). A cytotoxic gene therapy targeting SOX9-positive therapy-resistant medulloblastoma. Neuro-Oncology Pediatrics. https://doi.org/10.1093/neuped/wuaf005
Vancouver
Lin T, Hutter S, Vikström E, Rosén G, Bergström T, Holmberg KO, et al. A cytotoxic gene therapy targeting SOX9-positive therapy-resistant medulloblastoma. Neuro-Oncology Pediatrics. 2025. doi:10.1093/neuped/wuaf005
BibTeX
@article{Lin2025,
author = {Lin, Tong and Hutter, Sonja and Vikström, Elin and Rosén, Gabriela and Bergström, Tobias and Holmberg, Karl O and Zhao, Miao and Giraud, Géraldine and Swartling, Fredrik J},
title = {A cytotoxic gene therapy targeting SOX9-positive therapy-resistant medulloblastoma},
journal = {Neuro-Oncology Pediatrics},
year = {2025},
doi = {10.1093/neuped/wuaf005}
}
EUVIMED